7 recruiting, 3 completed, 3 terminated, 2 withdrawn. 11 Phase 1, 11 Phase 2.
Follow Relapsed Acute Myeloid Leukemia: new trials by email Literature Review of Relapsed Acute Myeloid Leukemia trials Research Report on Relapsed Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Imetelstat Combinations in Relapsed AML Imetelstat, Azacitidine, Venetoclax - Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | Douglas Tremblay | 36 | 2026-01-02 | 2026-04-22 |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Tagraxofusp, Cladribine (CLAD), Cytarabine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Stanford University | 20 | 2025-02-10 | 2026-04-14 |
| Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF - AML, Relapsed Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 20 | 2024-10-31 | 2024-12-27 |
| VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 67 | 2024-07-18 | 2024-08-05 |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Revumenib, Venetoclax, Azacitidine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 24 | 2024-04-19 | 2026-10-22 |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia CD371-specific/YSNVz/I-18 CAR T cells - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 15 | 2023-09-01 | 2026-10-06 |
| Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML Cytokine induced memory-like NK cells, Fludarabine, Ara-C - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 2 | Withdrawn | Washington University School of Medicine | 2023-06-30 | 2023-04-04 | |
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS Cytokine-induced memory-like NK cells, Fludarabine, Cyclophosphamide - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Withdrawn | Washington University School of Medicine | 2022-06-30 | 2022-03-11 | |
| Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia Venetoclax, Decitabine, Azacytidine, Cytarabine - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Unknown | Beijing 302 Hospital | 52 | 2022-05-01 | 2022-05-05 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-04-17 |
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies FHD-286, Low Dose Cytarabine, Decitabine - Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia | Phase 1 | Active not recruiting | Foghorn Therapeutics Inc. | 144 | 2021-06-14 | 2025-07-10 |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Flotetuzumab, Donor lymphocyte infusion - Relapsed Acute Myeloid Leukemia | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2021-05-20 | 2024-12-06 |
| Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML VAH regimen, VEN+HMA regimen - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Completed | Nanfang Hospital, Southern Medical University | 231 | 2018-12-03 | 2022-07-13 | |
| Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia Pembrolizumab, Decitabine - Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10 | 2016-12-16 | 2022-12-28 |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Ficlatuzumab, Cytarabine - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Terminated | C. Babis Andreadis | 17 | 2015-05-01 | 2020-03-24 |
| Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia cabozantinib - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | Massachusetts General Hospital | 18 | 2013-11-01 | 2017-07-21 |
Leukemia, Myeloid, Acute (18) · Myelodysplastic Syndromes (3) · Leukemia, Biphenotypic, Acute (2) · Neoplasm, Residual (2) · Recurrence (2) · Burkitt Lymphoma (1) · Chromosome Aberrations (1) · Leukemia, Myelomonocytic, Chronic (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Sarcoma, Myeloid (1)
Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Leukemia (18) · Leukemia, Myeloid (18) · Neoplasms by Histologic Type (18) · Neoplasms (17) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Bone Marrow Diseases (3) · Disease Attributes (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3)
Cytarabine (8) · Azacitidine (6) · Decitabine (5) · venetoclax (5) · Cladribine (2) · Granulocyte Colony-Stimulating Factor (2) · Interleukin-2 (2) · fludarabine (2) · Cyclophosphamide (1) · Dexamethasone (1) · Drug Therapy (1) · Filgrastim (1) · GRN163L peptide (1) · Immune Checkpoint Inhibitors (1) · Inotuzumab Ozogamicin (1)
Beijing 302 Hospital (3) · Washington University School of Medicine (3) · BeOne Medicines (1) · C. Babis Andreadis (1) · Douglas Tremblay (1) · Foghorn Therapeutics Inc. (1) · Kronos Bio (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Nanfang Hospital, Southern Medical University (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · St. Jude Children's Research Hospital (1) · Stanford University (1) · University of Washington (1)
United States (11) · China (3) · Spain (1)
Amanda Cashen, M.D. (1) · Amir Fathi, MD (1) · Charalambos Andreadis, MD (1) · Christopher S Hourigan, M.D. (1) · Douglas Tremblay, MD (1) · Hiroto Inaba, MD, PhD (1) · Jeffrey Bednarski, M.D., Ph.D. (1) · John Mascarenhas, MD (1) · Liu Qifa, MD (1) · Mark Geyer, MD (1) · Mary-Beth M. Percival (1) · Matthew Christopher, M.D., Ph.D. (1) · Sarah Reilly, MD (1) · Xiao-ning Gao (1)
PMID 40238563, PMID 40535475, PMID 40864984
P50CA171963 (1)